Wyss Institute at Harvard University的动态

Immune-modulating biomaterial technology developed in David Mooney’s group has been licensed to the Wyss startup Attivare Therapeutics, which will first use it to develop new types of immunotherapies for patients with solid tumors and heme malignancies who don’t respond to existing immunotherapies yet. #Immunotherapy #Startups #CancerTreatment https://lnkd.in/gf8zjRJM

  • SEM of biomaterial scaffold

要查看或添加评论,请登录